Nutrition Research Is Needed to Enhance Outcomes in Oncology

News
Video

Declan Walsh, MD, highlighted the need for nutrition research to enhance oncology care.

Nutrition is an important part of oncology care, but it is often underresearched and not discussed. As part of supportive care, this is an area that Declan Walsh, MD, believes is worth researching.

Walsh, chair of the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, noted that if patients have obesity at the time of diagnosis, it could affect treatment outcomes and create more adverse effects.

He stated that the field evolving around nutrition and malnutrition should be discussed more often, which may allow clinicians to give their patients more concrete answers on how to best live their lives.

Transcript:

There are lots of [next steps], because some of these areas have been quite neglected over the years. The one that I would pick most prominently is the area of nutrition and malnutrition. A huge proportion of patients with cancer in the United States who are diagnosed this year will [have] either overweight or [obesity]. That is a major issue in terms of, first of all, why somebody gets cancer. It also complicates the management of the disease if they, for example, have diabetes as a consequence of obesity, and it affects other outcomes in many ways. There’s also the issue of undernutrition: people losing weight. These are not uncommon problems. The majority of people now diagnosed [have] overweight or [obesity], and weight loss and severe weight loss are very common complications of cancer and, indeed, of cancer treatment and significantly change the outcome. I would be advocating for a major change in how we view the issues of nutrition and malnutrition in cancer care. Patients recognize this already, as a very common question when somebody’s diagnosed with cancer is, “What should I eat?” We don’t have a very good answer for that, unfortunately, [even though] these issues are highly prevalent and highly impactful in the trajectory of the illness.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content